GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (MEX:GSK N) » Definitions » Cyclically Adjusted FCF per Share

GSK (MEX:GSK N) Cyclically Adjusted FCF per Share : MXN78.77 (As of Mar. 2025)


View and export this data going back to 2003. Start your Free Trial

What is GSK Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

GSK's adjusted free cash flow per share for the three months ended in Mar. 2025 was MXN8.906. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN78.77 for the trailing ten years ended in Mar. 2025.

During the past 12 months, GSK's average Cyclically Adjusted FCF Growth Rate was 2.90% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 3.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 3.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of GSK was 83.40% per year. The lowest was -0.60% per year. And the median was 5.05% per year.

As of today (2025-06-27), GSK's current stock price is MXN791.00. GSK's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was MXN78.77. GSK's Cyclically Adjusted Price-to-FCF of today is 10.04.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of GSK was 16.26. The lowest was 9.11. And the median was 12.57.


GSK Cyclically Adjusted FCF per Share Historical Data

The historical data trend for GSK's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted FCF per Share Chart

GSK Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 81.45 87.89 65.98 59.64 67.58

GSK Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.10 63.16 69.78 67.58 78.77

Competitive Comparison of GSK's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted Price-to-FCF falls into.


;
;

GSK Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GSK's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=8.906/136.1000*136.1000
=8.906

Current CPI (Mar. 2025) = 136.1000.

GSK Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -2.482 100.100 -3.375
201509 0.505 100.200 0.686
201512 10.736 100.400 14.553
201603 -1.454 100.400 -1.971
201606 10.258 101.000 13.823
201609 16.483 101.500 22.102
201612 28.948 102.200 38.550
201703 8.603 102.700 11.401
201706 4.689 103.500 6.166
201709 17.173 104.300 22.409
201712 29.009 105.000 37.601
201803 6.517 105.100 8.439
201806 12.996 105.900 16.702
201809 20.236 106.600 25.836
201812 43.418 107.100 55.175
201903 4.608 107.000 5.861
201906 9.195 107.900 11.598
201909 25.082 108.400 31.491
201912 32.821 108.500 41.170
202003 8.993 108.600 11.270
202006 33.904 108.800 42.411
202009 3.023 109.200 3.768
202012 43.749 109.400 54.426
202103 -0.324 109.700 -0.402
202106 10.205 111.400 12.468
202109 18.992 112.400 22.997
202112 43.260 114.700 51.331
202203 25.446 116.500 29.727
202206 11.491 120.500 12.979
202209 9.373 122.300 10.431
202212 13.400 125.300 14.555
202303 -5.098 126.800 -5.472
202306 8.166 129.400 8.589
202309 17.983 130.100 18.812
202312 25.168 130.500 26.248
202403 4.050 131.600 4.188
202406 7.588 133.000 7.765
202409 16.504 133.500 16.825
202412 15.146 135.100 15.258
202503 8.906 136.100 8.906

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


GSK  (MEX:GSK N) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

GSK's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=791.00/78.77
=10.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of GSK was 16.26. The lowest was 9.11. And the median was 12.57.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


GSK Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK Business Description

Industry
Address
79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GSK Headlines

No Headlines